Arthritis, encompassing rheumatoid arthritis (RA) and osteoarthritis (OA), represents a major global health burden characterized by chronic inflammation, progressive cartilage degeneration, and functional disability. Although conventional therapies including non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and biologic disease-modifying anti-rheumatic drugs (DMARDs) provide symptomatic relief, their long-term use is often associated with significant adverse effects and economic limitations. Consequently, increasing attention has been directed toward traditional medicinal plants as potential multi-target therapeutic agents. Ethnopharmacological evidence from Ayurveda, Traditional Chinese Medicine, African traditional medicine, and other indigenous systems documents extensive use of plant-based remedies for inflammatory joint disorders. Phytochemical investigations reveal that bioactive constituents such as flavonoids (quercetin), polyphenols (curcumin, resveratrol), terpenoids (boswellic acids, andrographolide), alkaloids (berberine), and catechins (epigallocatechin gallate) exert anti-arthritic effects through modulation of key inflammatory pathways. These compounds suppress pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), inhibit NF-κB and JAK/STAT signaling, reduce oxidative stress, and prevent matrix metalloproteinase-mediated cartilage degradation. Preclinical and clinical studies support their efficacy in reducing disease activity, pain, and joint inflammation. However, challenges remain regarding standardization, safety profiling, pharmacokinetics, and large-scale randomized clinical validation. Integration of ethnopharmacology, phytochemistry, and modern molecular validation offers a promising framework for developing safer, evidence-based anti-arthritic therapeutics.